merger
Stelis, Strides and Steriscience merge to form new CDMO
October 22, 2024Research and Development CMDO, CPhI, Corporate, bangalore, merger
The CDMO launched earlier this year at the CPHI conference in Milan. The merger is comprised of Stelis Sciences, Strides …
Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology
August 10, 2023Business Services Glympse Bio, Oncology, Sunbird Bio, merger, oncology
Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to accelerate the development of both …
Axol Bioscience and CENSO Biotechnologies enter merger agreement
March 17, 2021Research and Development Axol Bioscience, Censo Biotechnologies, immune cell, merger, neuroscience
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO focused …
AstraZeneca to buy Alexion in $39 billion deal
December 14, 2020Sales and Marketing Alexion, AstraZeneca, merger
British-Swedish AstraZeneca is set to acquire American biopharmaceutical company Alexion for $39 billion, in a move that will see a …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
March 18, 2020Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, merger, pharma
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles on the road to regulatory …
Alexion to acquire Achillion Pharma for $930 million
October 16, 2019Research and Development, Sales and Marketing Alexion, achillion, merger, pharma
Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …
GSK closes the deal with Pfizer over $9.8 billion consumer healthcare merger
August 1, 2019Sales and Marketing GSK, Pfizer, merger, pharma
The $9.8 billion joint venture between major pharma firms GlaxoSmithKline and Pfizer to merge their consumer health operations has come …
GSK and Pfizer combine healthcare units in multibillion dollar deal
December 19, 2018Research and Development GSK, OTC, Pfizer, healthcare, merger
American multinational Pfizer and British firm GlaxoSmithKline are set to combine their consumer healthcare units in a venture worth billions. …
Alpine Immune Sciences boosts prospects with Nivalis merger
April 20, 2017Sales and Marketing Alpine Immune Sciences, Nivalis Therapeutics, merger
Alpine Immune Sciences has agreed a deal to merge with Nivalis Therapeutics, in an all-stock deal. The merger sees Alpine …
Jazz Pharmaceuticals to acquire Celator in $1.5 billion deal
May 31, 2016Manufacturing and Production, Sales and Marketing $1.5 billion, Vyxeos, acquisition, celator, jazz, leukaemia, merger, oncology
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that it has entered into a definitive merger agreement with Celator Pharmaceuticals (NASDAQ: CPXX) …
Pfizer to acquire Anacor in $5.2 billion deal
May 16, 2016Manufacturing and Production, Sales and Marketing 5.2 billion, FDA, Pfizer, acquisition, anacor, crisaborole, merger
Pfizer (NYSE: PFE) has acquired Anacor Pharmaceuticals (NASDAQ: ANAC) in a deal worth around $5.2 billion, or $99.25 per share. …
Quintiles to merge with IMS Health
May 3, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
Synta Pharmaceuticals announces merger with Madrigal
April 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger
Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
